Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 235 results for radiotherapy

  1. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

  2. High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer (IPG174)

    Evidence-based recommendations on high dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer. This involves using radiotherapy to treat the cancer from both outside of the body and from within the affected area.

  3. Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy (IPG615)

    Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.

  4. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

  5. Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (NG231)

    This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatments are used.

  6. Thyroid cancer: assessment and management (NG230)

    This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.

  7. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

  8. Haematological cancers: improving outcomes (NG47)

    This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.

  9. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

    This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.

  10. Lung cancer in adults (QS17)

    This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.

  11. Treatment for lung cancer

    The section of the NICE impact lung cancer report looking at how the disease is treated.

  12. How effective is stereotactic ablative radiotherapy compared with standard radiotherapy in the postoperative treatment of metastatic spinal cord compression (MSCC)?

    Question How effective is stereotactic ablative radiotherapy compared with standard radiotherapy in the postoperative...

  13. External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer?

    Question External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of external beam...

  14. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

  15. Managing meningioma: immediate versus deferred radiotherapy for incompletely excised grade I meningioma:- Is immediate or deferred radiotherapy better for incompletely excised grade I meningioma?

    meningioma: immediate versus deferred radiotherapy for incompletely excised grade I meningioma:- Is immediate or deferred...